NCT00802893
Endothelial Dysfunction, Isolated Systolic Hypertension
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This study is designed to assess the safety and efficacy of twice-daily oral dosing of 6R-BH4 to improve endothelial function, reduce systolic blood pressure and reduce arterial stiffness.
All
From 40 Years
No
6R-BH4, Placebo
Phase 2
Interventional
3
2008-12
2017-08-21
Baltimore, Maryland, United States
*required fields
"*" indicates required fields